Présentation des projets sur le site web

Chaque projet soutenu par Gebert Rüf Stiftung est présenté sur le site web de la fondation avec en particulier les données de base du projet. Par cette publication, la fondation informe sur les résultats du soutien accordé et contribue à la communication scientifique au sein de la société.


Procavea Biotech – Revolutionizing RNA Therapies: Beyond the Liver


The project management is responsible for the content of the information provided.

Données de projet

  • Numéro du projet: GRS-064/23 
  • Subside accordé: CHF 150'000 
  • Consentement: 31.10.2023 
  • Durée: 12.2023 - 06.2025 
  • Champs d'activité:  InnoBooster, seit 2018

Direction du projet

Description du projet

dRNA-based therapies have transformative potential in medicine. However, the limited delivery technologies available to turn these molecules into effective drugs holds back their true power. Procavea Biotech has developed an innovative solution to this problem: a unique RNA delivery platform based on nonviral protein cages. When compared to approved delivery methods and those in development, our technology has distinct advantages in its stability, engineerability, and manufacturing. Although a handful of RNA-based therapies have been approved, getting these molecules to organs other than the liver poses a significant challenge. At Procavea, our goal is to leverage the modularity of our delivery system and the programmability of genetic medicine to address currently intractable disease targets with new RNA-based drugs. Our proprietary technology puts us in a unique position to directly address the major barrier in RNA drug.

Etat/résultats intermédiaires

We have established the ‘OP’ delivery system, which is the first non-viral protein cage specifically designed for the delivery of oligonucleotides to cells. So far, we have demonstrated proof-of-concept in vitro for the delivery of small molecule drugs, DNA and RNA. Our current focus is in vivo translation of the technology platform for RNA delivery and determination of the disease indication that could benefit the most from a combination of our unique delivery technology with an RNA therapeutic.


Personnes participant au projet

Dr. Tom Edwardson, Project Leader
Dr. Michael Wetter, Senior Scientist
The project is supported by the supervision of Prof. Em. Donald Hilvert, Prof. Peter Kast and Prof. Markus Stoffel.

Dernière mise à jour de cette présentation du projet  22.02.2024